Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H17F3N2O4S |
Molecular Weight | 426.409 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(CC(O)=O)C2=CC=CN=C2N1CC3=CC=C(C=C3C(F)(F)F)S(C)(=O)=O
InChI
InChIKey=GFPPXZDRVCSVNR-UHFFFAOYSA-N
InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8H,9-10H2,1-2H3,(H,25,26)
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q9Y5Y4 Gene ID: 11251.0 Gene Symbol: PTGDR2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27310331 |
1.1 nM [Kd] |
PubMed
Title | Date | PubMed |
---|---|---|
Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy. | 2016 May |
|
An evaluation of fevipiprant for the treatment of asthma: a promising new therapy? | 2018 Dec |
|
Fevipiprant, a selective prostaglandin D(2) receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function. | 2019 Jun |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27354118
500 mg once daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26916831
Fevipiprant (QAW039) is currently in development for the treatment of allergic diseases. [3H]-QAW039 displayed high affinity for the human CRTh2 receptor (1.14 +/- 0.44 nM) expressed in Chinese hamster ovary cells, the binding being reversible and competitive with the native agonist prostaglandin D2.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB12011
Created by
admin on Sat Dec 16 08:19:31 GMT 2023 , Edited by admin on Sat Dec 16 08:19:31 GMT 2023
|
PRIMARY | |||
|
C166588
Created by
admin on Sat Dec 16 08:19:31 GMT 2023 , Edited by admin on Sat Dec 16 08:19:31 GMT 2023
|
PRIMARY | |||
|
BC-37
Created by
admin on Sat Dec 16 08:19:31 GMT 2023 , Edited by admin on Sat Dec 16 08:19:31 GMT 2023
|
PRIMARY | |||
|
872365-14-5
Created by
admin on Sat Dec 16 08:19:31 GMT 2023 , Edited by admin on Sat Dec 16 08:19:31 GMT 2023
|
PRIMARY | |||
|
CHEMBL3137332
Created by
admin on Sat Dec 16 08:19:31 GMT 2023 , Edited by admin on Sat Dec 16 08:19:31 GMT 2023
|
PRIMARY | |||
|
9682
Created by
admin on Sat Dec 16 08:19:31 GMT 2023 , Edited by admin on Sat Dec 16 08:19:31 GMT 2023
|
PRIMARY | |||
|
100000174166
Created by
admin on Sat Dec 16 08:19:31 GMT 2023 , Edited by admin on Sat Dec 16 08:19:31 GMT 2023
|
PRIMARY | |||
|
2PEX5N7DQ4
Created by
admin on Sat Dec 16 08:19:31 GMT 2023 , Edited by admin on Sat Dec 16 08:19:31 GMT 2023
|
PRIMARY | |||
|
Fevipiprant
Created by
admin on Sat Dec 16 08:19:31 GMT 2023 , Edited by admin on Sat Dec 16 08:19:31 GMT 2023
|
PRIMARY | |||
|
DTXSID501336031
Created by
admin on Sat Dec 16 08:19:31 GMT 2023 , Edited by admin on Sat Dec 16 08:19:31 GMT 2023
|
PRIMARY | |||
|
23582412
Created by
admin on Sat Dec 16 08:19:31 GMT 2023 , Edited by admin on Sat Dec 16 08:19:31 GMT 2023
|
PRIMARY |